Use of GLP-1 receptor agonists continues to shift rapidly, with early April developments highlighting changes in pricing models, drug access, regulatory oversight and personalized care. Here are five notable GLP-1 developments: 1. Pricing models diversify to boost access Novo Nordisk…
GLP-1s
The world’s two main GLP-1 drug manufacturers, Eli Lilly and Novo Nordisk, are taking different approaches with rolling out their recently approved GLP-1 pills for weight loss. Two oral GLP-1s, two very different commercial strategies. Health systems operating metabolic programs…
Researchers at the 23andMe Research Institute have identified genetic variants linked to weight loss and side effects among patients using GLP-1 receptor agonists. The study, published April 8 in Nature, analyzed data from 27,885 people who reported using GLP-1 medications.…
Amazon Pharmacy has begun offering Eli Lilly’s GLP-1 medication, Foundayo, via same-day delivery. The once-daily oral treatment is approved for adults with obesity or overweight with weight-related conditions. Patients with a valid prescription can order the drug with real-time pricing…
Novo Nordisk’s recently approved high-dose Wegovy formulation has entered the U.S. market and is available for $399 per month for self-paying patients, the drugmaker said April 7. In March, the FDA approved Wegovy HD, a 7.2-mg injection of semaglutide, as…
Advertisement
The FDA has clarified its policies regarding GLP-1s, stating that pharmacies must stop compounding GLP-1 drugs once branded versions are removed from the agency’s shortage list, signaling a narrower pathway for producing the high-demand therapies as supply stabilizes. Under federal…
The FDA on April 1 approved Eli Lilly’s daily GLP-1 pill, Foundayo, making it the U.S. market’s second oral GLP-1 drug for treating obesity. The first oral GLP-1 approved for weight loss is Novo Nordisk’s Wegovy pill (semaglutide), which the…
Novo Nordisk has launched a multimonth subscription program for Wegovy, which claims to offer more predictable, lower pricing for eligible self-pay patients who enroll through select telehealth providers. The program is currently available through Ro, WeightWatchers and LifeMD. Additional platforms,…
New Haven, Conn.-based Yale researchers are studying whether GLP-1 drugs may extend beyond diabetes and obesity treatment to address addiction, NBC Connecticut reported March 27. Rajita Sinha, PhD, director of the Yale Interdisciplinary Stress Center, studied semaglutide in people with obesity and…
GLP-1 medications like Ozempic, Wegovy, Mounjaro and Zepbound are FDA-approved for diabetes and weight loss, but growing evidence suggests their effects may extend beyond blood sugar and body fat, according to a March 27 analysis by The Washington Post. Researchers…